Results 11 to 20 of about 170,256 (261)

Estimating efficacy of favezelimab plus pembrolizumab relative to pembrolizumab in anti–PD-1–refractory Hodgkin lymphoma

Blood Advances
: Favezelimab plus pembrolizumab had promising efficacy in anti–programmed cell death protein 1 (PD-1)–refractory classical Hodgkin lymphoma in MK-4280-003; however, the contribution of favezelimab was unclear. Here, we assessed the relative contribution
Philippe Armand, Pier Luigi Zinzani, John Timmerman, Nathalie A. Johnson, David Lavie, Kannan Thiagarajan, Brian G. Topp, Pallavi Pillai, Alex F. Herrera   +8 more
doaj   +2 more sources

Pembrolizumab for all [PDF]

, 2023
The current approval indications for pembrolizumab are complex, reflecting the inclusion criteria of numerous clinical trials that led to approvals. Here we argue that allowing the use of pembrolizumab to any advanced solid tumor in any tumor type in any
Kim, Myung S, Prasad, Vinay
core   +1 more source

Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas [PDF]

, 2023
BackgroundTo date, single-agent immune checkpoint inhibitor (CPI) therapy has proven to be ineffective against biomarker-unselected extrapulmonary poorly differentiated neuroendocrine carcinomas (EP-PDNECs).
Kimberly Perez, Wang, Stephanie J, Chan, Jennifer A, Mulvey, Claire K, Pamela N. Munster, Emily K. Bergsland, Fong, Lawrence, Hope, Thomas A, Susan Calabrese, Grabowsky, Jennifer, Rahul R. Aggarwal, Diane Reidy-Lagunes, Li Zhang, Stephanie J. Wang, Perez, Kimberly, DeMore, April, Reidy-Lagunes, Diane, Claire K. Mulvey, Sippy Punn, Sofia Von Fedak, April DeMore, Kolli, Kanti Pallav, Bergsland, Emily K, Lawrence Fong, Von Fedak, Sofia, Zhang, Li, Raj, Nitya, Jennifer A. Chan, Jennifer Grabowsky, Thomas A. Hope, Punn, Sippy, Kanti Pallav Kolli, Aggarwal, Rahul R, Nitya Raj, Calabrese, Susan, Munster, Pamela N   +35 more
core   +1 more source

Unilateral Pneumonitis and Hydropneumothorax Following Pembrolizumab [PDF]

, 2022
A man in his 80s with metastatic melanoma presented with progressive dyspnea on exertion and dry cough after 7 cycles of pembrolizumab monotherapy. He was initially treated with antibiotics for community acquired pneumonia; however, his symptoms recurred
Christine Minerowicz, Andrew Sanchez, Harriet Kluger, Peter Kahn   +3 more
core  

Pembrolizumab induced-C3 glomerulonephritis and RBC cast nephropathy: a case report

BMC Nephrology, 2023
Background Immune checkpoint inhibitors (ICIs) are increasingly being used in the treatment of several cancers. Pembrolizumab is an anti-programmed cell death-1 (anti-PD-1) monoclonal antibody that is approved for the treatment of metastatic non-small ...
Zhi Yang, Huan Xu, Shenju Gou, Hongyan Wu, Zhangxue Hu   +4 more
doaj   +1 more source

Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer-Term Follow-Up From the Phase 3 KEYNOTE-240 Trial

Liver Cancer, 2023
Introduction: KEYNOTE-240 showed a favorable benefit/risk profile for pembrolizumab versus placebo in patients with sorafenib-treated advanced hepatocellular carcinoma (HCC); however, prespecified statistical significance criteria for overall survival ...
Philippe Merle, Masatoshi Kudo, Julien Edeline, Mohamed Bouattour, Ann-Lii Cheng, Stephen Lam Chan, Thomas Yau, Marcelo Garrido, Jennifer Knox, Bruno Daniele, Valeriy Breder, Ho Yeong Lim, Sadahisa Ogasawara, Stéphane Cattan, Yee Chao, Abby B. Siegel, Iván Martinez-Forero, Ziwen Wei, Chih-Chin Liu, Richard S. Finn   +19 more
doaj   +1 more source

Pembrolizumab: review of its current therapeutic uses [PDF]

, 2023
Background: Pembrolizumab is a humanized monoclonal antibody approved for human use in 2014 by the Food and Drug Administration (FDA) and in 2015 by the European Medicines Agency (EMA).
Silva, Rui, Fonseca, Sílvia, Oliveira, Susana   +2 more
core   +1 more source

Real-world treatment patterns and outcomes among individuals receiving first-line pembrolizumab therapy for recurrent/metastatic head and neck squamous cell carcinoma

Frontiers in Oncology, 2023
BackgroundPembrolizumab, a PD-1 immune checkpoint inhibitor, is approved as first-line (1L) treatment for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) as monotherapy or in combination with platinum and 5-fluorouracil ...
Christopher M. Black, Glenn J. Hanna, Liya Wang, Karthik Ramakrishnan, Daisuke Goto, Vladimir Turzhitsky, Gleicy M. Hair   +6 more
doaj   +1 more source

Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report

Journal for ImmunoTherapy of Cancer, 2019
Background Pembrolizumab, an anti-programmed cell death-1 protein monoclonal antibody, is effective for patients with advanced non-small-cell lung cancer.
Teppei Sugano, Masahiro Seike, Yoko Funasaka, Mai Yoshida, Ryoko Takayama, Ken Okamura, Asuka Nakanishi, Toru Tanaka, Susumu Takeuchi, Rintaro Noro, Yuji Minegishi, Kaoru Kubota, Hidehisa Saeki, Akihiko Gemma   +13 more
doaj   +1 more source

Pembrolizumab-induced pneumonitis with a perilymphatic nodular pattern in a lung cancer patient: A radio-pathologic correlation

Respiratory Medicine Case Reports, 2019
A 66-year-old Japanese man with recurrent adenocarcinoma of the lung p-stage IIIA (pT2bN2M0; version 8) on pembrolizumab was present with gradually worsening dyspnea.
Ryo Ueno, Masahiro Nemoto, Wataru Uegami, Junya Fukuoka, Masafumi Misawa   +4 more
doaj   +1 more source